|
|
INTERESTING IMAGE |
|
|
|
Year : 2020 | Volume
: 35
| Issue : 2 | Page : 176-177 |
|
|
Juvenile nasal angiofibroma on68Ga-DOTANOC PET/CT: Exploring theranostic avenues
Pirabu Sakthivel1, Alok Thakar1, Arun Prashanth2, Rakesh Kumar1, Suresh Chandra Sharma1, Rakesh Kumar2
1 Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute of Medical Sciences, New Delhi, India 2 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
Date of Submission | 20-Dec-2019 |
Date of Acceptance | 31-Jan-2020 |
Date of Web Publication | 12-Mar-2020 |
Correspondence Address: Prof. Rakesh Kumar Department of Nuclear Medicine, Division of Diagnostic Nuclear Medicine, All India Institute of Medical Sciences, New Delhi - 110 029 India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijnm.IJNM_207_19
Abstract | | |
Somatostatin (SST) cell surface receptors (SSTRs) are expressed in many different malignant, benign, and neuroendocrine tumors. SSTRs are also expressed in the endothelium of human vessels during angiogenesis and not in the nonproliferating vessels. We present a case of 19-year-old boy with juvenile nasal angiofibroma (JNA), who underwent68Ga-DOTANOC PET/CT to explore SSTRs expression and theranostic potential. The scan revealed high uptake in the tumor, and in certain areas, the uptake was similar to that of the pituitary gland. Performance of DOTANOC PET/CT in JNA opens up new frontiers with respect to radiological staging, early recurrence identification, better delineation from postoperative scar tissue, possible preoperative treatment with SST analogs, and perhaps even radiopharmaceutical based-ligand therapy of inoperable/residual/recurrent JNAs in the future.
Keywords: Angiofibroma, DOTANOC positron emission tomography computed tomography, juvenile nasopharyngeal angiofibroma
How to cite this article: Sakthivel P, Thakar A, Prashanth A, Kumar R, Sharma SC, Kumar R. Juvenile nasal angiofibroma on68Ga-DOTANOC PET/CT: Exploring theranostic avenues. Indian J Nucl Med 2020;35:176-7 |
How to cite this URL: Sakthivel P, Thakar A, Prashanth A, Kumar R, Sharma SC, Kumar R. Juvenile nasal angiofibroma on68Ga-DOTANOC PET/CT: Exploring theranostic avenues. Indian J Nucl Med [serial online] 2020 [cited 2022 Jul 3];35:176-7. Available from: https://www.ijnm.in/text.asp?2020/35/2/176/280457 |
A 19-year-old boy with an extensive clinicoradiologically diagnosed juvenile nasal angiofibroma (JNA) underwent68 Ga DOTANOC PET/CT scan to assess the somatostatin (SST) cell surface receptors (SSTRs) expression and to explore its theranostic potential. Only head-and-neck spot imaging was obtained to limit radiation exposure as the tumor is benign. The scan revealed heterogeneously increased tracer uptake in the soft tissue mass lesion, involving the right nasal cavity, the nasopharynx, and the ethmoid and sphenoid sinus (SUVmax3.3). The lesion was extending into the right pterygopalatine and infratemporal fossa causing the characteristic anterior bowing of posterior wall of the maxilla [“Holman miller antral bowing sign,” arrow in [Figure 1]d. The uptake was intense in certain areas of the tumors, similar to the uptake of pituitary gland (SUVmax3.6), concordant with the distribution of SSTRs. In addition, the intracranial extent of the tumor could be clearly demarcated as there was no uptake in the brain except for pituitary gland (axial, coronal, and sagittal PET [Figure 1]a, [Figure 1]b, [Figure 1]c, CT [Figure 1]d, [Figure 1]e, [Figure 1]f, and fused PET/CT images [Figure 1]g, [Figure 1]h, [Figure 1]i, respectively). The patient underwent surgical excision and the histopathology confirmed JNA. | Figure 1: DOTANOC scan revealing heterogeneously increased tracer uptake in the tumor along with characteristic anterior bowing of posterior wall of the maxilla (“Holman miller antral bowing sign”, arrow) (a). In addition, the intracranial extent of the tumor could be clearly demarcated as there was no uptake in the brain, except for pituitary gland – axial, coronal, and sagittal PET (a-c), CT (d-f), fused PET/CT images (g-i), respectively
Click here to view |
SST is a short peptide hormone with numerous autocrine, paracrine, and neurotransmitter regulatory functions.[1] SSTRs are expressed in many different malignant, benign, and neuroendocrine tumors. SSTRs are also expressed in the endothelium of human vessels during angiogenesis and not in the nonproliferating vessels.[2],[3] Hence, SSTRs expression may be expected in juvenile nasopharyngeal angiofibroma (JNA), an uncommon locally aggressive benign fibrovascular neoplasm arising from the posterior part of the nasal cavity in adolescent males.[4],[5] Gronkiewicz et al. described their findings in a group of 6 patients with juvenile nasal angiofibroma, in whom the68 Ga-DOTATATE PET data were correlated with immunohistochemistry for SST receptors.[6] Performance of DOTANOC PET/CT in JNA opens up new frontiers with respect to radiological staging, early recurrence identification, better delineation from postoperative scar tissue, possible preoperative treatment with SST analogs, and perhaps even peptide receptor-ligand therapy of inoperable/residual/recurrent JNAs in the future.
Informed consent
Informed consent was obtained from all individual participants included in the prospective clinical study (IECPG-432/27.06.2019), including the patient presented in this case report. A separate consent from the patient was obtained for publication of the case report.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References | |  |
1. | Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995;16:86-8. |
2. | Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003;20:255-64. |
3. | Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999;85:188-98. |
4. | Kukwa W, Andrysiak R, Kukwa A, Hubalewska-Dydejczyk A, Gronkiewicz Z, Wojtowicz P, et al. (99m) TC-octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasopharyngeal angiofibromas. Head Neck 2011;33:1739-46. |
5. | López F, Triantafyllou A, Snyderman CH, Hunt JL, Suárez C, Lund VJ, et al. Nasal juvenile angiofibroma: Current perspectives with emphasis on management. Head Neck 2017;39:1033-45. |
6. | Gronkiewicz Z, Kukwa W, Krolicki L, Cyran-Chlebicka A, Pawlak D, Stankiewicz C, et al. (68) Ga-DOTATATE PET in juvenile angiofibroma. Future Oncol 2016;12:1483-91. |
[Figure 1]
|